The association of risk factors, circulatory biomarkers and antihypertensive medications with preeclampsia: a Mendelian randomisation analysis
Abstract
Background: While many risk factors for pre-eclampsia (PE) have been identified, their causal role and the potential preventive effects of specific antihypertensive drug classes remain unclear.
Methods: We examined the potential causal effect of 22 risk factors and two genetically proxied antihypertensive drugs (Beta-blockers and Calcium channel blockers) on PE development and its two related conditions, PE-HTP (PE or other maternal hypertension) and PE-SGA (PE or delivery of a small for gestational age neonate). Using summary statistics from published genome-wide association studies, we employed two-sample Mendelian randomization (MR) using Wald ratio or inverse variance weighted. MR Egger, weighted median and MR-PRESSO (Pleiotropy RESidual Sum and Outlier), Multivariable MR (MVMR) and Bayesian colocalization analyses were performed where appropriate.
Results: Maternal body mass index (BMI), systolic blood pressure (SBP) and diastolic BP (DBP) were significantly associated with all PE outcomes. Higher BMI was associated with increased risk of PE (Odds ratio (OR) = 1.50, P = 1.58 × 10⁻⁸), PE-HTP (OR = 1.72, P = 1.04 × 10⁻¹⁷) and PE-SGA (OR = 1.35, P = 2.06 × 10⁻⁵). Elevated SBP showed strong associations with PE (OR = 2.74, P = 3.90 × 10⁻²⁶), PE-HTP (OR = 3.64, P = 4.23 × 10⁻³⁷) and PE-SGA (OR = 2.21, P = 5.01 × 10⁻¹⁸). Increased DBP was significantly linked to PE (OR = 2.33, P = 7.03 × 10⁻¹⁷), PE-HTP (OR = 3.08, P = 9.59 × 10⁻²⁷) and PE-SGA (OR = 2.04, P = 8.38 × 10⁻¹⁴). Age at menarche was associated with PE-HTP, but this effect was mediated by BMI. Genetically proxied calcium channel blockers (CCB) were linked to with lower odds of PE and PE-HTP in the DBP-based drug-target MR (OR per SD reduction = 0.31, P = 0.001 and OR per SD reduction = 0.17, P = 5.12 × 10 − 6 , respectively), with consistent findings observed in the complementary SBP-based analysis.
Conclusions: The findings validate the significant role of cardiovascular factors in the PE pathogenesis and highlight new therapeutic possibilities.
Related
- Management of Chronic Antihypertensive Medications in the Perioperative Period
- Association of preconception and pregnancy dietary zinc and selenium intake with preeclampsia risk: results from a large birth cohort study
- Factors Associated With Uncontrolled Blood Pressure and Its Association With Cardiovascular and All-Cause Mortality Among Adults Receiving Antihypertensive Therapy: A Retrospective Cohort Study Using NHANES 2013-2018 Linked Mortality Data
- Association of Peak Circulatory Power with Invasive Hemodynamic Severity in Pulmonary Hypertension
- Longitudinal association between a combination of four persistent patient-reported cardiopulmonary and circulatory symptoms and incident ADL/IADL difficulties
BibTeX
@article{wang2026association,
title = {{The association of risk factors, circulatory biomarkers and antihypertensive medications with preeclampsia: a Mendelian randomisation analysis}},
author = {Sze Sen Wang and Devendra Meena and Jingxian Huang and Georg W Otto and Makrina Savvidou and Abbas Dehghan},
journal = {BMC Medicine},
year = {2026},
month = oct,
doi = {10.1186/s12916-026-05310-z},
url = {https://link.springer.com/article/10.1186/s12916-026-05310-z},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The association of risk factors, circulatory biomarkers and antihypertensive medications with preeclampsia: a Mendelian randomisation analysis
AU - Sze Sen Wang
AU - Devendra Meena
AU - Jingxian Huang
AU - Georg W Otto
AU - Makrina Savvidou
AU - Abbas Dehghan
PY - 2026
DA - 2026/10/30
JO - BMC Medicine
DO - 10.1186/s12916-026-05310-z
UR - https://link.springer.com/article/10.1186/s12916-026-05310-z
AB - Background: While many risk factors for pre-eclampsia (PE) have been identified, their causal role and the potential preventive effects of specific antihypertensive drug classes remain unclear. Methods: We examined the potential causal effect of 22 risk factors and two genetically proxied antihypertensive drugs (Beta-blockers and Calcium channel blockers) on PE development and its two related conditions, PE-HTP (PE or other maternal hypertension) and PE-SGA (PE or delivery of a small for gestational age neonate). Using summary statistics from published genome-wide association studies, we employed two-sample Mendelian randomization (MR) using Wald ratio or inverse variance weighted. MR Egger, weighted median and MR-PRESSO (Pleiotropy RESidual Sum and Outlier), Multivariable MR (MVMR) and Bayesian colocalization analyses were performed where appropriate. Results: Maternal body mass index (BMI), systolic blood pressure (SBP) and diastolic BP (DBP) were significantly associated with all PE outcomes. Higher BMI was associated with increased risk of PE (Odds ratio (OR) = 1.50, P = 1.58 × 10⁻⁸), PE-HTP (OR = 1.72, P = 1.04 × 10⁻¹⁷) and PE-SGA (OR = 1.35, P = 2.06 × 10⁻⁵). Elevated SBP showed strong associations with PE (OR = 2.74, P = 3.90 × 10⁻²⁶), PE-HTP (OR = 3.64, P = 4.23 × 10⁻³⁷) and PE-SGA (OR = 2.21, P = 5.01 × 10⁻¹⁸). Increased DBP was significantly linked to PE (OR = 2.33, P = 7.03 × 10⁻¹⁷), PE-HTP (OR = 3.08, P = 9.59 × 10⁻²⁷) and PE-SGA (OR = 2.04, P = 8.38 × 10⁻¹⁴). Age at menarche was associated with PE-HTP, but this effect was mediated by BMI. Genetically proxied calcium channel blockers (CCB) were linked to with lower odds of PE and PE-HTP in the DBP-based drug-target MR (OR per SD reduction = 0.31, P = 0.001 and OR per SD reduction = 0.17, P = 5.12 × 10 − 6 , respectively), with consistent findings observed in the complementary SBP-based analysis. Conclusions: The findings validate the significant role of cardiovascular factors in the PE pathogenesis and highlight new therapeutic possibilities.
SN - 1741-7015
ER -